TY - JOUR
T1 - Obstructive sleep apnea and heart failure
AU - Somers, Virend K.
AU - Calvin, Andrew D.
AU - Albuquerque, Felipe N.
AU - Adachi, Taro
N1 - Funding Information:
This study was supported by operating grants MOP-82731 and IS2-95225 from the Canadian Institutes of Health Research (CIHR), the latter in conjunction with an unrestricted research grant from Philips-Respironics Inc. in accordance with the policies of the CIHR's University-Industry program. Dr. Kasai was supported by an unrestricted research fellowship from Fuji-Respironics Inc . Dr. Bradley received grant support from Philips-Respironics Inc. in partnership with the CIHR .
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 2009/12
Y1 - 2009/12
N2 - Opinion statement: Obstructive sleep apnea (OSA) exerts several effects that may be particularly deleterious in patients with heart failure (HF). OSA should be considered especially in HF patients who are obese or have the metabolic syndrome, systemic hypertension, or pulmonary hypertension. HF patients in whom OSA is suspected should undergo a full evaluation by a sleep specialist, including a polysomnogram, to diagnose OSA and differentiate this disease from central sleep apnea. Those found to have OSA should then receive continuous positive airway pressure and/or other interventions, and standard disease management strategies should be used to maximize compliance. Those who cannot tolerate continuous positive airway pressure may be candidates for mandibular advancement devices or surgical therapies including tracheostomy. Standard HF medications should be used to treat HF, and optimization of fluid balance may help minimize OSA severity. However, it is still unknown whether treatment of OSA in HF patients will reduce hospitalizations or mortality.
AB - Opinion statement: Obstructive sleep apnea (OSA) exerts several effects that may be particularly deleterious in patients with heart failure (HF). OSA should be considered especially in HF patients who are obese or have the metabolic syndrome, systemic hypertension, or pulmonary hypertension. HF patients in whom OSA is suspected should undergo a full evaluation by a sleep specialist, including a polysomnogram, to diagnose OSA and differentiate this disease from central sleep apnea. Those found to have OSA should then receive continuous positive airway pressure and/or other interventions, and standard disease management strategies should be used to maximize compliance. Those who cannot tolerate continuous positive airway pressure may be candidates for mandibular advancement devices or surgical therapies including tracheostomy. Standard HF medications should be used to treat HF, and optimization of fluid balance may help minimize OSA severity. However, it is still unknown whether treatment of OSA in HF patients will reduce hospitalizations or mortality.
UR - http://www.scopus.com/inward/record.url?scp=70449499080&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70449499080&partnerID=8YFLogxK
U2 - 10.1007/s11936-009-0047-z
DO - 10.1007/s11936-009-0047-z
M3 - Review article
C2 - 19930982
AN - SCOPUS:70449499080
SN - 1092-8464
VL - 11
SP - 447
EP - 454
JO - Current Treatment Options in Cardiovascular Medicine
JF - Current Treatment Options in Cardiovascular Medicine
IS - 6
ER -